Portfolio Companies

Phase 1 data for FPI-1434 anticipated to be reported in the second half of 2022 Company continues to build a diversified pipeline of TATs and advance manufacturing and actinium...
Read more

Targovax has entered into an agreement with Oslo University Hospital (OUS) to test TG01 in a phase 1/2 trial in 20 patients with RAS mutant multiple myelomaThe trial will be spons...
Read more

Oslo, Norway, 6 May 2022 Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the first quarter 2022 on Friday, 13 May 2022. A presentation by No...
Read more

Gothenburg, May 5, 2022 - Vicore Pharma Holding AB (publ) publishes the interim report for the first quarter 2022. Important events during the first quarter In February, an ...
Read more

Conference call and webcast at 8:30am ET CHICAGO--(BUSINESS WIRE)--May 4, 2022-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company devel...
Read more

Published: 2022-05-04 BONESUPPORT Holding AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first q...
Read more

STOCKHOLM — May 4, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematologi...
Read more

REDWOOD CITY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lu...
Read more

Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small moleculesAdcendo building a world class team of experienced biotec...
Read more

Second publication reports on CD37-targeting imaging approach to select NHL patients who might respond best to Humalutin® treatment  Oslo, Norway, 3 May 2022 Nordic Na...
Read more